vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and LAKELAND FINANCIAL CORP (LKFN). Click either name above to swap in a different company.

CareDx, Inc. is the larger business by last-quarter revenue ($117.7M vs $69.7M, roughly 1.7× LAKELAND FINANCIAL CORP). LAKELAND FINANCIAL CORP runs the higher net margin — 38.0% vs 2.4%, a 35.6% gap on every dollar of revenue. Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs 0.7%).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

Amscot Financial is an American financial services company headquartered in Tampa, Florida. Founded in 1989 by Ian MacKechnie, Amscot Financial provides non-bank consumer financial services through a network of retail branches located exclusively within Florida. Amscot's core services include check cashing, bill payment, prepaid access cards, payday loans, free money orders, ATMs in every branch, wire transfers, notary services, fax services, and postage. Amscot Financial operates nearly 240 ...

CDNA vs LKFN — Head-to-Head

Bigger by revenue
CDNA
CDNA
1.7× larger
CDNA
$117.7M
$69.7M
LKFN
Higher net margin
LKFN
LKFN
35.6% more per $
LKFN
38.0%
2.4%
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
0.7%
LKFN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CDNA
CDNA
LKFN
LKFN
Revenue
$117.7M
$69.7M
Net Profit
$2.8M
$26.5M
Gross Margin
Operating Margin
1.0%
Net Margin
2.4%
38.0%
Revenue YoY
39.0%
Net Profit YoY
31.8%
EPS (diluted)
$0.05
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
LKFN
LKFN
Q1 26
$117.7M
$69.7M
Q4 25
$108.4M
$69.8M
Q3 25
$100.1M
$69.0M
Q2 25
$86.7M
$66.4M
Q1 25
$84.7M
$63.8M
Q4 24
$86.6M
$63.6M
Q3 24
$82.9M
$61.2M
Q2 24
$92.3M
$68.7M
Net Profit
CDNA
CDNA
LKFN
LKFN
Q1 26
$2.8M
$26.5M
Q4 25
$-4.1M
$29.9M
Q3 25
$1.7M
$26.4M
Q2 25
$-8.6M
$27.0M
Q1 25
$-10.4M
$20.1M
Q4 24
$87.7M
$24.2M
Q3 24
$-10.6M
$23.3M
Q2 24
$-4.6M
$22.5M
Operating Margin
CDNA
CDNA
LKFN
LKFN
Q1 26
1.0%
Q4 25
-5.6%
52.1%
Q3 25
-0.2%
46.4%
Q2 25
-12.8%
49.6%
Q1 25
-15.8%
38.0%
Q4 24
97.5%
46.0%
Q3 24
-16.6%
45.3%
Q2 24
-7.9%
39.2%
Net Margin
CDNA
CDNA
LKFN
LKFN
Q1 26
2.4%
38.0%
Q4 25
-3.8%
42.8%
Q3 25
1.7%
38.3%
Q2 25
-9.9%
40.6%
Q1 25
-12.2%
31.5%
Q4 24
101.3%
38.1%
Q3 24
-12.8%
38.1%
Q2 24
-5.0%
32.8%
EPS (diluted)
CDNA
CDNA
LKFN
LKFN
Q1 26
$0.05
$1.04
Q4 25
$-0.08
$1.16
Q3 25
$0.03
$1.03
Q2 25
$-0.16
$1.04
Q1 25
$-0.19
$0.78
Q4 24
$1.60
$0.94
Q3 24
$-0.20
$0.91
Q2 24
$-0.09
$0.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
LKFN
LKFN
Cash + ST InvestmentsLiquidity on hand
$77.9M
$85.6M
Total DebtLower is stronger
$183.6M
Stockholders' EquityBook value
$749.0M
Total Assets
$411.1M
$7.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
LKFN
LKFN
Q1 26
$77.9M
$85.6M
Q4 25
$177.2M
$141.3M
Q3 25
$194.2M
$192.8M
Q2 25
$186.3M
$310.2M
Q1 25
$230.9M
$235.2M
Q4 24
$260.7M
$168.2M
Q3 24
$240.9M
$160.2M
Q2 24
$228.9M
$121.2M
Total Debt
CDNA
CDNA
LKFN
LKFN
Q1 26
$183.6M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
$30.0M
Q2 24
$0
$55.0M
Stockholders' Equity
CDNA
CDNA
LKFN
LKFN
Q1 26
$749.0M
Q4 25
$303.1M
$762.4M
Q3 25
$311.1M
$747.4M
Q2 25
$327.4M
$709.9M
Q1 25
$379.3M
$694.4M
Q4 24
$378.4M
$683.8M
Q3 24
$273.2M
$699.1M
Q2 24
$264.7M
$654.5M
Total Assets
CDNA
CDNA
LKFN
LKFN
Q1 26
$411.1M
$7.1B
Q4 25
$413.2M
$7.0B
Q3 25
$432.3M
$6.9B
Q2 25
$444.3M
$7.0B
Q1 25
$489.6M
$6.9B
Q4 24
$491.1M
$6.7B
Q3 24
$477.0M
$6.6B
Q2 24
$466.8M
$6.6B
Debt / Equity
CDNA
CDNA
LKFN
LKFN
Q1 26
0.25×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
0.04×
Q2 24
0.00×
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
LKFN
LKFN
Operating Cash FlowLast quarter
$4.3M
Free Cash FlowOCF − Capex
$514.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
LKFN
LKFN
Q1 26
$4.3M
Q4 25
$21.4M
$114.9M
Q3 25
$37.4M
$36.1M
Q2 25
$9.9M
$16.2M
Q1 25
$-26.6M
$28.9M
Q4 24
$21.9M
$102.5M
Q3 24
$12.5M
$18.0M
Q2 24
$18.9M
$21.0M
Free Cash Flow
CDNA
CDNA
LKFN
LKFN
Q1 26
$514.0K
Q4 25
$103.8M
Q3 25
$31.1M
Q2 25
$14.1M
Q1 25
$27.1M
Q4 24
$93.9M
Q3 24
$15.3M
Q2 24
$18.6M
FCF Margin
CDNA
CDNA
LKFN
LKFN
Q1 26
0.4%
Q4 25
148.7%
Q3 25
45.0%
Q2 25
21.2%
Q1 25
42.5%
Q4 24
147.6%
Q3 24
25.0%
Q2 24
27.0%
Capex Intensity
CDNA
CDNA
LKFN
LKFN
Q1 26
Q4 25
15.9%
Q3 25
7.3%
Q2 25
3.2%
Q1 25
2.8%
Q4 24
13.6%
Q3 24
4.4%
Q2 24
3.5%
Cash Conversion
CDNA
CDNA
LKFN
LKFN
Q1 26
1.54×
Q4 25
3.84×
Q3 25
22.30×
1.37×
Q2 25
0.60×
Q1 25
1.44×
Q4 24
0.25×
4.24×
Q3 24
0.77×
Q2 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

LKFN
LKFN

Net Interest Income$56.8M81%
Noninterest Income$12.9M19%

Related Comparisons